Rivastigmine, offered in capsule and transdermal patch formulations, effectively treats mild to moderately severe Alzheimer's dementia and dementia linked with Idiopathic Parkinson's disease.
By inhibiting cholinesterase, it elevates acetylcholine levels in the brain, mitigating cognitive decline.
Dosage initiation starts conservatively and incrementally, guided by individual tolerability.
Caution is warranted for potential drug interactions and adverse reactions, necessitating vigilant monitoring for optimal patient care.
